Total (n = 35) | Group 1 (n = 16) | Group 2 (n = 19) | P-value | |
---|---|---|---|---|
Post-AGVI BCVA | 1.22 ± 0.79 | 1.21 ± 0.69 | 1.25 ± 0.86 | 0.961† |
Unfavorable visual outcome (%) | 12 (34.3) | 7 (43.8) | 5 (26.3) | 0.311‡ |
IOP at the time of AGVI (mmHg) | 36.8 ± 9.36 | 41.3 ± 7.4 | 33.1 ± 9.2 | 0.003† |
Postoperative IOP | ||||
3 months after AGVI | 17.9 ± 7.1 | 17.8 ± 9.7 | 18.0 ± 3.6* | 0.108† |
6 months after AGVI | 17.6 ± 6.1** | 16.3 ± 3.7* | 18.7 ± 7.3* | 0.513† |
12 months after AGVI | 15.2 ± 4.0** | 14.5 ± 3.7* | 15.7 ± 4.2* | 0.327† |
Surgical success at one year based on IOP (%) | 30 (85.7) | 13 (81.3) | 17 (89.5) | 0.642‡ |
Complications (%) | ||||
Anterior chamber hyphema | 6 (17.1) | 3 (18.8) | 3 (15.8) | 1.000‡ |
Tube obstruction | 1 (2.9) | 1 (6.3) | 0 (0) | 0.457‡ |
Vitreous hemorrhage | 8 (22.9) | 4 (25.0) | 4 (21.1) | 1.000‡ |
Early hypotony with choroidal detachment or collapsed anterior chamber | 1 (2.9) | 1 (6.3) | 0 (0) | 0.441‡ |
Endophthalmitis | 0 (0) | 0 (0) | 0 (0) | 1.000‡ |